Clinical bottom line
Artificial intelligence (AI) applied to tumor angiogenic vessel morphology shows promising potential as a non-invasive tool to predict pathological features relevant to tumor progression and response to anti-angiogenic therapies. Early evidence suggests that AI algorithms analyzing vascular patterns, vessel maturity, and endothelial markers may enhance the precision of pathological assessment beyond conventional histology. However, current data remain preliminary and largely experimental, requiring further validation in diverse tumor types and clinical settings before routine clinical adoption.
What the evidence shows
Tumor angiogenesis is a critical hallmark of cancer, influencing tumor growth, metastasis, and therapeutic response. Morphological features of tumor blood vessels—such as vessel density, diameter, branching patterns, and endothelial cell characteristics—reflect the underlying biology of tumor vasculature and its interaction with the microenvironment. AI approaches leveraging image analysis and computational modeling have been developed to quantify these features objectively and predict pathological and clinical outcomes.
Arakelyan et al. (2002) described a computational algorithm simulating vessel formation and maturation processes, demonstrating its utility in predicting the effects of anti-angiogenic and anti-maturation therapies on tumor vascular growth. This early work laid a foundation for AI-driven vascular morphology analysis by modeling dynamic angiogenic processes.
More recently, studies have focused on circulating endothelial cells and tumor endothelial markers as surrogates for tumor angiogenesis. For example, the role of aneuploid circulating tumor cells and CD31+ circulating tumor endothelial cells in predicting and monitoring anti-angiogenic therapy efficacy in advanced non-small cell lung cancer (NSCLC) was reviewed, highlighting the potential of endothelial markers combined with AI to stratify therapeutic response (2021 DOI:10.1002/1878-0261.13092/v1/review1).
Nanotechnology-based approaches integrating AI have also been explored. Platelet-membrane-coated nanoparticles delivering vascular disrupting agents combined with anti-angiogenic drugs showed improved tumor vessel impairment, suggesting that AI-guided morphological assessment could optimize such targeted therapies [3].
Lu Jiahao et al. (2026) discussed the complex balance between tumor vessel normalization and excessive pruning induced by anti-angiogenic therapy, emphasizing the need for precise morphological assessment to avoid systemic vascular toxicity. AI tools analyzing vessel morphology could help identify this therapeutic window by quantifying vascular changes more accurately than traditional pathology.
Caveats and uncertainty
Despite encouraging findings, several limitations temper enthusiasm for immediate clinical implementation. Most AI models for tumor angiogenic vessel morphology remain in preclinical or early translational stages, with limited validation in large, prospective clinical cohorts. Variability in tumor types, heterogeneity of angiogenic patterns, and differences in imaging modalities challenge the generalizability of current algorithms.
Moreover, the biological complexity of tumor vasculature—including interactions with immune cells, stromal components, and extracellular matrix—may not be fully captured by morphological features alone. Integrating multi-omic data alongside vascular morphology may be necessary to improve predictive accuracy.
Technical challenges include standardization of image acquisition, annotation, and algorithm training to ensure reproducibility. The clinical relevance of AI-derived morphological metrics must be correlated with meaningful endpoints such as progression-free survival, overall survival, or response to specific therapies.
How this may change practice
If validated, AI-based analysis of tumor angiogenic vessel morphology could augment pathological evaluation by providing quantitative, reproducible metrics that predict tumor aggressiveness and therapeutic response. This could facilitate personalized anti-angiogenic treatment strategies, optimizing dosing and timing to maximize efficacy while minimizing toxicity.
Such tools may also enable real-time monitoring of vascular changes during therapy, guiding adaptive treatment modifications. Integration with circulating endothelial cell biomarkers could further enhance non-invasive disease monitoring.
Pathologists may increasingly collaborate with computational scientists to incorporate AI vascular morphology assessments into diagnostic workflows, complementing traditional histopathology and molecular profiling.